Zevaskyn (prademagene zamikeracel) - MEDICAID - SOUTH CAROLINA

Zevaskyn (prademagene zamikeracel) is covered as an autologous, gene‑modified cell‑sheet therapy surgically applied to wounds to rebuild skin in individuals with recessive dystrophic epidermolysis bullosa (RDEB) due to COL7A1 mutations (FDA‑approved April 2025) for patients aged 6–65. Coverage is limited to wound treatment, supplied as a single‑dose of up to 12 cellular sheets manufactured from the patient’s biopsy, and requires Medical Director review with referral to the Corporate Transplant Department for case‑by‑case authorization; non‑RDEB uses are not supported in this excerpt.

"Clinical scenarios described in the text: blistering, chronic wounds, erosions, scarring, and internal blistering in more severe forms of EB."

Sign up to see full coverage criteria, indications, and limitations.